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Abstract
Death receptor (DR3) 3 is a member of the TNFR superfamily. Its ligand is TNF-like ligand 1A (TL1A), a member of the TNF
superfamily. TL1A/DR3 interactions have been reported to modulate the functions of T cells, NK, and NKT cells and play
a crucial role in driving inflammatory processes in several T-cell-dependent autoimmune diseases. However, TL1A
expression and effects on B cells remain largely unknown. In this study, we described for the first time that B cells from
human blood express significant amounts of DR3 in response to B cell receptor polyclonal stimulation. The relevance of
these results has been confirmed by immunofluorescence analysis in tonsil and spleen tissue specimens, which showed the
in situ expression of DR3 in antigen-stimulated B cells in vivo. Remarkably, we demonstrated that TL1A reduces B-cell
proliferation induced by anti-IgM-antibodies and IL-2 but did not affect B-cell survival, suggesting that TL1A inhibits the
signal(s) important for B-cell proliferation. These results revealed a novel function of TL1A in modulating B-cell proliferation
in vitro and suggest that TL1A may contribute to homeostasis of effector B-cell functions in immune response and host
defense, thus supporting the role of the TL1A/DR3 functional axis in modulating the adaptive immune response.
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Introduction
Death receptor (DR) 3 (TNFRSF25/Apo3/LARD/TR3/
TRAMP/WSL-1) is a member of the TNFR superfamily and,
within that family, of the DR subfamily, whose members contain
a death domain (DD) as part of their intracellular domain [1–5].
Among the DR subfamily members, DR3 shows the highest
homology to TNFR1 [3,4]. However, unlike TNFR1 that shows
a ubiquitous expression, DR3 expression is restricted to lympho-
cyte-enriched tissues, including peripheral blood leukocytes,
thymus and spleen, and it has been shown to be especially up-
regulated in activated T cells [2,6].
The ligand for DR3 is TNF-like ligand 1A (TL1A), a member of
the TNF superfamily [7–10]. TL1A is expressed in a variety of cell
types, including activated endothelial cells, monocytes, macro-
phages, dendritic cells, and T cells [7,11–15]. Like other TNF
members, TL1A contains a predicted transmembrane domain and
a bioactive, proteolytically cleaved truncated form that can be
released as a soluble factor [7,8]. TL1A expression is highly
regulated and induced by inflammatory stimuli [7,11,15,16].
The TL1A/DR3 axis has been shown to costimulate T cells to
produce a wide variety of cytokines and promote cell proliferation
of activated T cells in vitro and in vivo [11,13]. TL1A biases T cells
to differentiate towards Th1 and Th17 phenotype [12,13,17] and
modulates Treg expansion and functions [18–20]. Moreover, DR3
can modulate NK [6,21] and NKT-cell functions [22]. Consis-
tently, recent studies have reported an essential role for the TL1A/
DR3 pathway in generating T-cell host defense response [23,24].
Several studies in mice deficient in DR3 or TL1A have revealed
a specific role for DR3 in enhancing proliferation of effector T
cells at the site of tissue inflammation in autoimmune disease
models driven by diverse T-cell subsets, with the level of TL1A
expression correlating with the severity of inflammation [25,26].
Moreover, chronic expression of TL1A induces a distinct in-
terleukin-13-dependent inflammatory disease of small intestine
[20]. Together, these studies have contribute to shape a model for
TL1A/DR3 axis suggesting that TL1A produced by endothelial
cells, dendritic cells, and monocytes in inflamed tissue provides
costimulation for effector and memory T cells leading to greater
pathogenicity in diverse autoimmune diseases [25,26].
Over the last few years, major efforts have been made to
understand the physiologic and pathologic role of TL1A in T cells.
In contrast, little is known on expression and function of DR3 in B
cells. To address this issue, in this study we explored the expression
of DR3 in human B cells derived from peripheral blood and
investigated its possible role in modulating B-cell proliferation. We
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described that B cells activated in vitro by the B cell receptor (BCR)
stimulation express DR3 molecule. Further, DR3 was expressed
in vivo in antigen-stimulated B cells of tonsil germinal centers (GC).
Remarkably, we found that TL1A significantly reduces pro-
liferation of suboptimally activated B cells. Our data suggest
a novel role for the TL1A/DR3 axis in modulating proliferation of
activated B cells.
Materials and Methods
Cell and Tissue Samples
Cryopreserved peripheral blood mononuclear cells (PBMC)
from 10 human blood buffy coats and formalin-fixed paraffin-
embedded human tissue tonsil (n = 4) and spleen (n = 3) sections
were used in this study. Buffy coats were collected at the
Hematology Unit, Azienda Ospedaliera Universitaria Integrata
(AOUI) in Verona (Italy); tonsil specimens were obtained from
hyperplastic tonsils of subjects undergoing tonsillectomy and
collected at the Pathological Anatomy Unit, AOUI, Verona
(Italy); spleen specimens were obtained from normal spleen
removed after traumatic injuries and collected at the Pathological
Anatomy Unit, AOUI, Verona (Italy). PBMCs were isolated by
Ficoll-hypaque centrifugation (Lymphoprep, Nicomed, Oslo,
Norway) and suspended in freezing medium for storage in liquid
nitrogen. Upon thawing, cell viability consistently exceeded 95%
in all samples. Cells were washed twice in PBS and then
resuspended in the appropriate buffer or medium. PBMC-derived
B cells were isolated by negative selection using the Human B-Cell
Enrichment Kit (without CD43 depletion; Stem Cell Technolo-
gies, Vancouver, Canada). After separation, B cells were washed
twice and counted. Cell purity as assessed with CD19 staining was
routinely above 98%.
Ethics Statement
Blood and tissue samples were collected under a protocol
approved by the local Ethics Committee (Comitato Etico per la
Sperimentazione – AOUI) and data were analyzed anonymously.
In accordance with the Declaration of Helsinki, all blood donors
provided written informed consent for the collection and use of
their blood samples for research purposes. For the use of tissue
Figure 1. DR3 surface expression in B cells. (A) Representative flow cytometry histograms of surface DR3 expression in purified B cells, in resting
conditions or following stimulation with anti-IgM (n= 10). Analyses were gated on lymphocytes (based on forward and side scatter), living cells
(7AAD-negative), and B cells (CD19-positive). (B) Surface DR3 expression in resting and BCR-stimulated B cells (n = 10). Data are expressed as DR3-
expression median fluorescence intensity (MFI) divided by isotype-matched control (relative median fluorescence intensity = RMFI). Comparison
between resting and anti-IgM-stimulated B cells was performed by the two-sample Wilcoxon signed rank sum test. (C) Surface DR3 expression in IgM-
negative (IgM-) and IgM-positive (IgM+) B cells (n = 10). Data are expressed as difference in DR3-expression median fluorescence intensity (MFI)
divided by isotype-matched control (relative median fluorescence intensity = RMFI). Comparison between IgM-negative and IgM-positive B cells was
performed by the Mann Whitney test. Data are represented as mean 6 SEM. (D) Western blot analysis of cell lysates of purified B cells (n = 4), in
resting conditions or following stimulation with anti-IgM. The level of DR3 induction after anti-IgM stimulation is reported as fold change.
doi:10.1371/journal.pone.0060136.g001
TL1A Modulates B-Cell Proliferation
PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e60136
samples, the local Ethics Committee (Comitato Etico per la
Sperimentazione – AOUI) approved the anonymous retrospective
use of samples consisting of ‘‘diagnostic remnants’’ without written
consent release, as also specifically stated in the Italian law,
according to the directive issued on March 1st 2012 from the
Italian Privacy Authority (Deliberazione n. 85) (12A03185)
(complying with EU directives).
Cell Stimulation
Peripheral blood (PB) purified B cells were stimulated by
incubating with sulfate latex beads (2.3 mm diameter) (Interfacial
Dynamics Corporation, Portland, OR) [27] coated with goat
F(ab’)2 anti-human IgM (20 mg/ml) (Southern Biotech, Birming-
ham, AL) in 24-well plates, at 56106 cells/ml, for the indicated
time. At the end of the incubation, the cells were subjected to flow
cytometry or biochemical analysis.
Flow Cytometry Analyses
PB purified B cells stimulated or not with sulfate latex beads
coated with anti-IgM for 24 h were harvested, washed, resus-
pended in PBS and incubated with either PE-conjugated anti-
human DR3 mAb (clone JD3, BioLegend, London, UK) or
isotype control antibody on ice for 45 min. The cells were then
stained with APC-conjugated anti-CD19 mAb (BD Biosciences,
San Jose, CA) and 7-amino-actinomycin (7AAD, BD Biosciences)
for 15 min on ice. Approximately 16104 gated events were
Figure 2. Expression of DR3 in tissue tonsil in vivo. Immunofluorescence analysis of DR3 in a representative tissue tonsil section (n = 4).
Pseudocolour images of DR3 200x (A) and 1000x (B), CD3 (1000x) (C), CD20 (1000x) (D). (E–F) Merged pseudocolour images of CD20 (blue), CD3
(yellow), DR3 (red) and DNA (green); (200x) (E), (1000x) (F). GC: germinal center; M: mantle zone.
doi:10.1371/journal.pone.0060136.g002
Figure 3. Expression of DR3 in tissue spleen in vivo. Immunofluorescence analysis of DR3 in a representative tissue spleen section (n = 3).
Pseudocolour images of CD20 (1000x) (A) and DR3 (1000x) (B). (C) Merged pseudocolour image of CD20 (green), DR3 (red) and DNA (blue) (200x)
(1000x).
doi:10.1371/journal.pone.0060136.g003
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acquired for each sample on FACSCanto cytometer (Becton
Dickinson, San Jose, CA). Flow cytometry data were gated using
the FlowJo software (TreeStar, Ashland, OR). All analyses were
gated on lymphocytes based on forward and side scatter, on living
cells (7AAD-negative), and on B cells (CD19-positive). Fluores-
cence signals were normalized with respect to the controls by
calculating the ratio between the median fluorescence intensity
(MFI) of DR3 and the respective isotype-matched, irrelevant
monoclonal antibody.
For immunophenotype analysis of B cells stimulated with anti-
IgM, IL-2 in the presence or absence of TL1A, PB purified B cells
were plated in a 96-well plate at 16105/well in duplicate and
stimulated with 2 mg/ml of soluble anti-IgM, 20 U/ml IL-2 in
presence or absence of 100 ng/ml human recombinant TL1A.
Cells were harvested at 24, 48, 72 and 96 h and stained with
7AAD, FITC-conjugated anti-CD38, PE-conjugated anti-CD20,
PECy7-conjugated anti-CD19, APC-conjugated anti-CD138, and
APC-H7-conjugated anti-CD45 mAb (all from BD Biosciences).
Approximately, 16104 gated events were acquired for each sample
on a FACSCanto (Becton Dickinson) and analyzed using FlowJo
software (TreeStar). Multiparameter phenotyping of B cells was
performed gating on lymphocytes, based on forward and side
scatter, on living cells according to 7AAD staining, and then on B
cells on the basis of CD19 and CD45 expression. When indicated,
IgM-positive or -negative (IgM+; IgM2) B cells were gated for
analysis.
Western Blot Analysis
PB purified B cells stimulated or not with sulfate latex beads
coated with anti-IgM for 24 h, as described above, were lysed in
80 ml of lysis buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 0.5% Igepal, 1% Triton X-100; all
supplied by Sigma-Aldrich, Milan, Italy) supplemented with
1 mM Na3VO4, 1 mM PMSF and protease inhibitors (all supplied
by Sigma-Aldrich). Protein concentrations were normalized using
BCA reagent according to the manufacturer’s protocol (Sigma-
Aldrich). Fifteen mg proteins were separated on a 10% SDS-
polyacrylamide gel and electrotransferred to a PVDF membrane.
The membrane was treated with blocking buffer (5% BSA in Tris
buffered saline +0.1% Tween-20 [TBST]) and then incubated
with anti-DR3 primary antibody (Cell Signaling Technology,
Danvers, MA, USA). Blots were developed using chemilumines-
cent substrate Lite A Blot Plus (Euroclone S.p.A., Siziano, Italy)
and horseradish peroxidase (HRP)-conjugated secondary antibo-
dies. b-actin was used as standard. Quantification of bands was
performed with ImageJ software (http://rsb.info.nih.gov/ij/).
Chemiluminescent signals were normalized calculating the ratio
between DR3 expression of each sample and the respective b-actin
signal. Changes in DR3 expression was expressed by calculating
the fold difference in normalized DR3 of anti-IgM stimulated cells
divided by resting cells (i.e. fold change).
Immunofluorescence
Staining was performed on 4 mm formalin-fixed paraffin-
embedded tissue tonsil and spleen sections. Deparafinization was
obtained by a 20-minute wash in xylene and hydration by
sequential washes in 100%, 85%, and 70% ethanol solutions
(10 min), distilled water (10 min) and twice in PBS (10 min each).
Sections were bathed in ER2 solution (pH 8, Leica Biosystems,
Newcastle, UK) at 85uC for 30 min for antigen retrieval and then
cooled 15 min at room temperature and 15 min in water. Next,
the slides were rinsed with distilled water for two minutes, and
then with PBS. Incubation with each antibody was preceded by
20 min protein block (DAKO, Carpinteria, CA, USA). Slides were
incubated with primary antibody in dilution solution (Leica
Biosystems) (DR3, clone JD3, dil. 1:50, Abcam, Cambridge,
UK; CD20, clone L26, Leica Biosystems, dil. 1:100; CD3, clone
SP7, Leica Biosystems, dil. 1:150) overnight at 4uC (DR3) or for
1 h at room temperature (CD20 and CD3) in a humid chamber.
Anti-mouse (DR3 and CD20) or anti-rabbit (CD3) biotinilated
antibody was incubated for 30 min at room temperature. Then
Qdot Streptavidin Conjugates (QD565, QD605, QD655, Invitro-
gen, Eugene, OR, USA) were incubated in PBS (40 nM) for 1 h at
RT in a humid chamber. Slides were then rinsed in PBS twice
3 min each and incubated with Qnuclear Deep Red Stain
(Invitrogen; dil. 1:1000 in PBS) for 20 min. After rinsing slides
again in PBS, they were washed in graded ethanol solution series
(30 s each) consisting of 30%, 50%, 70%, and 90% ethanol, and
then for 1 min with Toluene (Sigma-Aldrich). Slides were
mounted with Qdot Qmount mounting media (Invitrogen).
Images were acquired with microscope BX61, Olympus optical
CO. LTD. (Tokyo, Japan) and with proper filter sets (QD565,
QD605, QD655, Chroma Technology Corporation, Bellow Falls,
VT, USA), and for nuclear staining Cy5 filter set (Olympus).
Images were finally analyzed and elaborated by CellF software v.
3.3 (Olympus Soft Imaging Solutions GmbH, Munster, Germany).
Proliferation Analysis
PB purified B cells were resuspended at 16106/ml in PBS at
37uC supplemented with 0.1% BSA and labeled with 5 mM CFSE
Figure 4. B-cell proliferation induced by increasing doses of anti-IgM antibodies in the presence of IL-2. CFSE-labeled purified B cells
were activated with different doses of anti-IgM antibodies (1, 2, 5, 10, 20 mg/ml) in the presence or absence of 20 U/ml IL-2 for 96 h, and analyzed for
CFSE dilution. Three parameters were calculated (division index, percentage (%) divided and number of divisions) and represented in distinct graphs.
doi:10.1371/journal.pone.0060136.g004
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(Invitrogen) for 10 min at 37uC. The reaction was quenched
adding ice-cold RPMI 1640 medium supplemented with 10% FBS
and incubating on ice for 5 min. Cells were then washed three
times with ice-cold RPMI 1640 medium supplemented with 10%
FBS. CFSE-labeled cells were plated in a 96-well plate at 16105/
well in duplicate and stimulated with the indicated concentrations
of soluble anti-IgM and 20 U/ml IL-2 (Proleukin, Novartis, Siena,
Italy), 2.5 mg/ml CpG oligodeoxynucleotides type B 2006-G5
(CpG-ODN, Invivogen, Toulouse, France) or 50 ng/ml poly-
histidine-tagged CD40L (R&D System, Abington, UK), in the
presence or absence of the indicated concentrations of human
recombinant TL1A (Peprotech, London, UK). For stimulation
with anti-IgM and IL-2, cells were harvested after 24, 48, 72 and
96 h and stained with 7AAD, PECy7-conjugated anti-CD19 and
Figure 5. TL1A reduces proliferation of activated B-cells. (A) Representative flow cytometry histograms of CFSE-labeled B cells stimulated
(empty curve) or not (grey curve) with 2 mg/ml (n = 8) or 20 mg/ml (n = 3) anti-IgM and 20 U/ml IL-2 for 96 h, in the presence or absence of 100 ng/ml
TL1A. Bold numbers indicate percentage of proliferating cells. Analyses are gated on lymphocytes (based on forward and side scatter), and living
(7AAD-negative) B cells (CD19-positive). (B) Proliferating B cells were stimulated with 2 mg/ml (n = 8) or 20 mg/ml (n = 3) anti-IgM and 20 U/ml IL-2 for
96 h, in the presence or absence of 100 ng/ml TL1A. Three parameters were calculated (division index, % divided and number of divisions) and
represented as distinct histograms. Data are represented as mean6SEM. Comparison between treatments was performed by the two-sample
Wilcoxon signed rank sum test. (C) Proliferation of B cells stimulated with 2 mg/ml anti-IgM, 20 U/ml IL-2 for 96 h, in the presence of different doses
of TL1A (n = 3). Three parameters were calculated (division index, % divided and number of divisions) and represented as separated histograms. Data
are represented as mean6SEM. * = p,0.05. (D) Time-course experiment (n = 2) of CFSE-labeled purified B cells stimulated with 2 mg/ml anti-IgM,
20 U/ml IL-2; 2 mg/ml anti-IgM, 20 U/ml IL-2, 100 ng/ml TL1A; 100 ng/ml TL1A; or medium. Three parameters were calculated (division index, %
divided and number of divisions) and represented as separated graphs.
doi:10.1371/journal.pone.0060136.g005
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APC-conjugated anti-CD27 mAb (all from BD Biosciences). For
stimulation with anti-IgM and CpG-ODN or CD40L, cells were
harvested after 96 h and stained with 7AAD and APC-conjugated
anti-CD19. Approximately, 36104 gated events were acquired for
each sample on a FACSCanto (Becton Dickinson).
CFSE dilution was analyzed on B cells using FlowJo software
(TreeStar) comparing three different parameters: (i) division index,
i.e. the average number of divisions that a cell has undergone; (ii)
percentage divided, i.e. the percentage of cells that divided in the
original sample; (iii) number of cell divisions, calculated from the
number of cells in each population. All analyses were gated on
lymphocytes based on forward and side scatter, living cells
according to 7AAD staining, B cells on the basis of CD19
expression, and discriminating CD27-positive (CD27+) and
2negative (CD272) cells.
Apoptosis Assay
Cell apoptosis was detected using the annexinV-FITC/
propidium iodide (PI) detection kit (Bender Med System, Vienna,
Austria), according to the manufacturer’s recommended protocol.
Briefly, purified B cells were stimulated with 2 mg/ml soluble anti-
IgM, 20 U/ml IL-2 (Proleukin, Novartis) in the presence or
absence of 100 ng/ml human recombinant TL1A (Peprotech).
After 24, 48, 72 and 96 h, the cells were harvested and stained
with FITC-conjugated annexinV for 10 min. PI was added just
before the analysis on a FACSCanto flow cytometer (Becton
Dickinson). At least 16104 events were acquired. Samples were
analyzed by FlowJo software (TreeStar). Viable cells were defined
as annexinV-negative and PI-negative. All analyses were gated on
CD19 expression.
Statistical Analysis
All graphing and statistical analyses were performed using
GraphPad Prism software. Results obtained in independent
experiments are expressed as mean and SEM. As data were not
normally distributed, the two-sample Wilcoxon signed rank sum
test was used to compare DR3 expression between resting and
anti-IgM-stimulated cells and compare B cell proliferation
between samples subjected to different stimuli. The Mann
Whitney test was used to compare DR3 expression between
IgM-positive and IgM-negative B cells. Student t test was used to
compare proliferation between CD27-positive and CD27-negative
B-cell subsets, for which two independent experiments have been
performed. Two-way ANOVA was used to compare cell survival
between samples subjected to different stimuli. Differences
between data were considered significant for p-values ,0.05.
Results
Expression of DR3 in B Cells
To characterize DR3 expression at a protein level in human B
cells, first we analyzed surface DR3 expression in resting and anti-
IgM-activated B cells obtained from human PBMC samples
(n = 10) by flow cytometry. B cells expressed minimal, if any,
detectable levels of DR3 surface expression when they were both
uncultured (time 0, data not shown) and cultured for 24 h (Fig. 1A
and Fig. 1B). Following stimulation with anti-IgM, a statistically
significant increase of DR3 expression (p= 0.002) was observed in
B cells (Fig. 1A and Fig. 1B). Induced DR3 expression, measured
as the fold-change in MFI between anti-IgM-stimulated and
resting conditions, varied amongst the B cells, ranging from 1.6- to
13-fold change (Fig. 1B). Further, calculating the variance (s2) of
DR3 fluorescence intensity confirmed the high variability of DR3
expression among anti-IgM-stimulated samples (s2 = 14.1). As
expected, augmented DR3 expression following stimulation with
anti-IgM was specifically detected in the IgM-expressing B-cell
subset but not in IgM-negative B cells (p,0.001; Fig. 1C).
In order to confirm flow cytometry data by an independent
assay, Western blot analysis was performed on B-cell total lysate
extracts. DR3 exists as at least 11 isoforms generated by pre-
mRNA alternative splicing. The major isoform has a molecular
weight of 47 kD [28]. Accordingly, several isoforms were identified
in B cells by antibodies directed against the intracellular domain of
DR3 (Fig. 1D). Those included the isoform at 47 kD and an
additional isoform migrating at approximately 40 kD (Fig. 1D).
Consistently with the flow cytometry data, minimal, if any, DR3
levels were detected in resting B cells whereas BCR stimulation
with anti-IgM antibodies induced a significant increase of all DR3
isoforms (Fig. 1D).
Expression of DR3 in vivo
To confirm the relevance of our findings, we first analyzed DR3
expression in tonsil specimens (n = 4) by using a four-color
immunofluorescence approach. Figure 2A shows that tonsil
germinal centers (GC) contained high numbers of cells that
strongly expressed DR3 (Fig. 2B shows a magnified inset). These
DR3-positive cells were of both T and B lineage, respectively
identified on the basis of CD3 (Fig. 2C) or CD20 (Fig. 2D)
expression, as shown by the merged pseudocolor image of DR3,
CD20, CD3, and DNA (Fig. 2E and the magnified inset Fig. 2F).
The highest expression of DR3 was observed in the GC
centroblasts whereas intra-follicular T-cells and centrocytes
showed a weak signal (Fig. 2E). In contrast, mantle-zone (M) B
cells showed no detectable expression of DR3 (Fig. 2E). Because
GC centroblasts are B cells activated by the antigen encounter,
Figure 6. TL1A induces similar reduction extents of proliferation in the CD27+ and CD272 B-cell subsets. CFSE-labeled purified B cells
(n = 2) were activated with 2 mg/ml anti IgM, 20 U/ml IL-2 for 96 h, in presence or absence of 100 ng/ml TL1A. Analyses were gated on lymphocytes
(based on forward and side scatter), living (7AAD-negative) and CD19-positive cells and discriminating CD27+ and CD272 cells. Three parameters
were calculated (division index, % divided and number of divisions) and represented as separated histograms. Data are represented as mean6SEM.
* = p,0.05.
doi:10.1371/journal.pone.0060136.g006
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these data are consistent with our in vitro findings showing that
DR3 is expressed in BCR-stimulated B cells.
To further confirm our findings, we analyzed DR3 expression in
spleen specimens (n = 3) containing a few number of GCs (and
therefore a few antigen-activated B cells) by using a four-color
immunofluorescence approach. This analysis revealed the occa-
sional presence of only a few DR3-positive cells in the spleen white
pulp (Fig. 3A). These DR3-positive cells were identified as B cells
on the basis of CD20 expression (Fig. 3B). Figure 3C shows the
merged pseudocolor image of DR3, CD20, and DNA. These data
support our in vitro findings showing that unstimulated B cells dot
not express DR3 molecule.
TL1A Reduces B-cell Proliferation
Data on DR3 expression prompted us to investigate whether
DR3 was biologically active in B cells. As it has been described
that TL1A/DR3 interactions enhance cell proliferation of
suboptimally activated T cells in vitro [12,16,29], we sought to
investigate whether DR3 expressed on B cells could also modulate
B-cell proliferative response. Therefore, B cells were incubated
with different doses of anti-IgM (1, 2, 5, 10, 20 mg/ml) in the
presence or absence of 20 U/ml IL-2 at different times (24, 48, 72
and 96 h). Dose-response curves indicated that, in the presence of
IL-2, 2 mg/ml anti-IgM induced a suboptimal proliferative
response whereas 20 mg/ml anti-IgM evoked maximal prolifera-
tive response (Fig. 4). Importantly, under these conditions, B cells
expressed DR3 at any time-point analyzed, i.e. 24, 48, 72 and
96 h (data not shown). Time course curves indicated that maximal
proliferative response was achieved at 96 h (data not shown).
Therefore, the concentrations of 2 mg/ml or 20 mg/ml anti-IgM,
20 U/ml IL-2, in the presence or absence of 100 ng/ml human
recombinant TL1A, and a 96-h time point were considered
appropriate conditions to observe any eventual proliferation
modulation mediated by TL1A.
Remarkably, in contrast to its effects on T-cell proliferation
[13,16,29], TL1A significantly decreased proliferation of B cells
activated with suboptimal doses of anti-IgM (p= 0.008) whereas
did not affect B-cell proliferation induced by saturating doses of
anti-IgM (Fig. 5A and Fig. 5B). Dose-response studies demon-
strated that maximal response in modulating B-cell proliferation
was achieved with 100 ng/ml TL1A (p= 0.015) (Fig. 5C). In
addition, time-course experiments revealed that the ability of
TL1A to modulate B-cell proliferation was observed at the same
time to the onset of proliferative activity following stimulation with
anti-IgM and IL-2 (72 h) and remained up to 96 h of incubation
(Fig. 5D). No effect was observed on cell proliferation when B cells
were incubated with TL1A alone, in the absence of anti-IgM and
IL-2 (Fig. 5D).
Next, we explored whether the TL1A-mediated inhibitory
effects on B-cell proliferation could differentially affect memory
(CD27+) and naı¨ve (CD272) B cells. As shown in Fig. 6,
recombinant TL1A induced similar extents of proliferation
reduction in the two B-cell subsets. Cell-proliferation reduction
was not paralleled by significant changes in CD19, CD20, CD38
and CD138 expression, as detected by flow cytometry analysis of B
cells activated with anti-IgM and IL-2 at different time points
upon TL1A treatment (24, 48, 72, 96 h) (Fig. 7).
Figure 7. TL1A does not modulate surface expression of CD19, CD20, CD38, and CD138 in B cells. Data from a representative
experiment (n = 2) on CD19, CD20, CD38, and CD138 expression in B cells activated with 2 mg/ml anti-IgM, 20 U/ml IL-2 in the presence or absence of
100 ng/ml TL1A at different time point (24, 48, 72, 96 h).
doi:10.1371/journal.pone.0060136.g007
Figure 8. TL1A does not modulate B-cell proliferation induced by anti-IgM and CpG-ODN or CD40L. (A) Proliferating B cells were
stimulated with different doses of anti-IgM antibodies (1, 2, 5, 10, 20 mg/ml) and of 2.5 mg/ml CpG-ODN for 96 h, in the presence or absence of
100 ng/ml TL1A (n = 4). Three parameters were calculated (division index, % divided and number of divisions) and represented as separated graphs.
(B) Proliferating B cells were stimulated with different doses of anti-IgM antibodies (1, 2, 5, 10, 20 mg/ml) in the presence of 50 ng/ml CD40L for 96 h,
in the presence or absence of 100 ng/ml TL1A (n = 4). Three parameters were calculated (division index, % divided and number of divisions) and
represented as separated graphs.
doi:10.1371/journal.pone.0060136.g008
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Figure 9. TL1A does not affect B-cell survival. Purified B cells were activated with 2 mg/ml anti-IgM, 20 U/ml IL-2 for 24, 48,72 and 96 h, in
presence or absence of 100 ng/ml TL1A, stained with annexinV/PI and analyzed by flow cytometry. Analyses were gated on CD19-positive cells. (A)
Dot plots representatives of three independent experiments. Bold numbers indicate percentage of cells in each quadrant. (B) Percentage of viable
cells (annexinV-negative/PI-negative) following incubation with 2 mg/ml anti-IgM, 20 U/ml IL-2; 2 mg/ml anti-IgM, 20 U/ml IL-2, 100 ng/ml TL1A;
medium. Data are represented as mean6SEM. * = p,0.05; ns = not significant.
doi:10.1371/journal.pone.0060136.g009
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To assess the specificity of TL1A effect to B cell proliferative
stimuli, B cells were induced to proliferate by treatment with
different doses of anti-IgM in conjunction with CpG-ODN or
CD40L, in the presence or absence of TL1A. Figure 8 shows that
TL1A did not affect B cell proliferation induced by either anti-
IgM+CpG-ODN or anti-IgM+CD40L, at any concentration of
anti-IgM (range 1–20 mg/ml). CpG-ODN or CD40L in the
absence of anti-IgM did not induce B-cell proliferation (Fig. 8).
TL1A does not Affect B-cell Survival
Depending on the cellular context in which DR3 is triggered, its
activation can result in induction of apoptosis [5,30]. This raised
the possibility that the reduced CFSE dilution induced in B cells by
TL1A was due to reduced survival. To test this, purified B cells
were incubated with anti-IgM and IL-2 in the presence or absence
of recombinant TL1A and cell survival was measured by
annexinV/PI staining and flow cytometry at 24, 48, 72 and
96 h following TL1A treatment. As expected, stimulation with
anti-IgM, IL-2 protected B cells from spontaneous apoptosis
whereas no significant changes in cell viability were observed in
anti-IgM/IL-2 activated B cells treated with TL1A (Fig. 9), thus
demonstrating that reduced CFSE dilution induced in B cells by
TL1A was due to decreased cell division and not to reduced
survival.
Discussion
DR3 [2,6] has been shown to modulate the functions of T cells,
NK and NKT cells [6,11,16,17,21,22]. B cells express very little
DR3 full-length mRNA whereas they express combination of the
other isoforms, encoding potentially secreted molecules [5].
However, DR3 protein expression and its effects on B cells
remain largely unknown. In this study, we describe for the first
time that B cells from human blood express significant amounts of
DR3 in response to the polyclonal stimulation of BCR. The
relevance of these results has been confirmed by immunofluores-
cence analysis of tonsil and spleen tissue specimens, which show
that antigen-stimulated B cells (centroblasts) in tonsil GC express
high levels of DR3 whereas a few DR3-positive B cells are
detectable in the white pulp of spleens showing rare GC.
Remarkably, we demonstrated that TL1A reduces B-cell
proliferation induced by anti-IgM-antibodies and IL-2. This result
is opposite of that observed in T cells, where TL1A/DR3
interactions costimulate proliferation of suboptimally activated
cells [13,16,29]. However, consistently with TL1A effects on T
cells, our data support the notion that TL1A acts as a cell
modulator that cannot function without antigenic activation
signals.
TL1A-induced inhibition of B-cell proliferation appears to be
independent of apoptotic mechanisms since TL1A does not trigger
cell death in activated B cells. This is consistent with previous
studies showing that TL1A induces apoptosis in overexpression
cell systems and in DR3-expressing cell lines, whereas primary T
cells do not undergo apoptosis when treated with TL1A [7].
In this study, we used peripheral blood B cells, which consist of
naı¨ve and memory B cells. We show that the extent of proliferation
inhibition induced by TL1A is similar in the two B-cell subsets, in
contrast to what observed in T cells, in which the effects mediated
by TL1A are more pronounced in memory versus naı¨ve T cells
[29,31]. Further, TL1A-mediated inhibition of proliferation is not
paralleled by changes in B-cell phenotype, thus indicating that
TL1A does not affect B-cell differentiation.
Although changes in IgM expression induced by TL1A could
not be evaluated in this experimental condition (the presence of
anti-IgM induces internalization of IgM molecules, irrespectively
of the presence of TL1A), TL1A does not affect IgD and IgG
surface expression on B cells activated with anti-IgM and IL-2
(data not shown). These data, although partial, are in agreement
with previous data indicating a normal antibody production in the
absence of DR3, in murine models of experimental autoimmune
encephalomyelitis (EAE) [16] and experimental antigen-induced
arthritis (AIA) [32].
TL1A-mediated inhibition of proliferation is specific to anti-
IgM and IL-2 stimuli, since TL1A does not affect proliferation
induced by other B-cell specific stimuli, such as anti-IgM in
conjunction with CpG-ODN or CD40 ligand. This finding
suggests that in vivo TL1A can modulate B-cell proliferation in
a context conditioned by the presence of IL-2.
The mechanisms underlying TL1A inhibitory effects on B cells
are unclear yet; however, the finding that TL1A reduces
proliferation of purified B cells rules out that other cells can
indirectly mediate this effect. TL1A is mainly expressed by
macrophages, dendritic cells, endothelial cells, and T cells
activated by inflammatory stimuli [7,11]. In contrast, B cells are
unable to produce TL1A, as assessed by immunofluorescence and
ELISA analyses, both in resting conditions and upon activation
with anti-IgM (data not shown). Therefore, several cell types can
produce TL1A cytokine potentially acting on B cells in various
physiological and pathological settings, whilst the existence of an
autocrine production of TL1A can be reasonably excluded.
Herein, we show that B-cell proliferation is inhibited by TL1A
in vitro and one may speculate a similar effect in vivo, where it may
have relevant implications in both physiological and pathological
immune responses. TL1A costimulates T-cell proliferation and
cytokine production of activated T cells in vitro [11,12], thus
defining a role for TL1A as a T-cell costimulator. In addition,
TL1A biases T-cell differentiation toward Th1 and Th17 T cells
[12,13,17] and modulate Treg expansion and functions [18–20],
therefore suggesting a role in regulating the adaptive immune
response. In pathological settings, TL1A interactions with DR3-
expressing T cells have been shown to play a crucial role in driving
inflammatory processes at the site of inflammation in several T-
cell-dependent autoimmune disease models, such as rheumatoid
arthritis (RA) and inflammatory bowel disease (IBD)
[16,25,26,31,33–34]. The effects of TL1A described in T cells,
both in vitro and in animals models of autoimmune diseases may be
apparently in contrast to the inhibitory effects mediated by TL1A
on B-cell proliferation herein described. However, it has been
shown that effects of TL1A on T-cell differentiation in vitro are
largely dependent on experimental settings. For example, exoge-
nous TL1A suppresses the ability of human CD4+ T cells to
differentiate into Th17 in the presence of IL-2 [17,29] whereas
promotes Th17 fate when IL-2 is limiting [17]. Also, TGF-b-
induced T-cell differentiation into Treg is inhibited by TL1A
when IL-2 is not limiting whereas TL1A does not suppress and can
even enhance Treg development when IL-2 is not added
[26,29,35]. Therefore, TL1A homeostatic functions seem to be
highly dependent on the context of the immune response that is
being modulated. Accordingly, the inhibitory effects of TL1A on
B-cell proliferation may also depend on the specific experimental
setting in vitro. Similarly, in vivo TL1A may be able to limit B-cell
expansion in a particular condition of the immune response.
This study shows that TL1A is able to inhibit B-cell proliferation
in vitro and suggests that TL1A may contribute to homeostasis of
effector B-cell functions in immune response and host defense.
Together with previous data from the literature, these results
support an important role for TL1A in modulating the cell-
mediated immune responses.
TL1A Modulates B-Cell Proliferation
PLOS ONE | www.plosone.org 10 April 2013 | Volume 8 | Issue 4 | e60136
Author Contributions
Conceived and designed the experiments: MTS. Performed the experi-
ments: CC OL AB LP E. Zoratti. Analyzed the data: CC OL AB LP E.
Zoratti E. Zanolin MK AZ CT MAC GP MTS. Wrote the paper: CC
MTS.
References
1. Kitson J, Raven T, Jiang YP, Goeddel DV, Giles KM, et al. (1996) A death-
domain-containing receptor that mediates apoptosis. Nature 384: 372–375.
2. Marsters SA, Sheridan JP, Donahue CJ, Pitti RM, Gray CL, et al. (1996) Apo-3,
a new member of the tumor necrosis factor receptor family, contains a death
domain and activates apoptosis and NF-kB. CurrBiol 6: 1669–1676.
3. Chinnaiyan AM, O’Rourke K, Yu GL, Lyons RH, Garg M, et al. (1996) Signal
transduction by DR3, a death domain-containing receptor related to TNFR-1
and CD95. Science 274: 990–992.
4. Bodmer JL, Burns K, Schneider P, Hofmann K, Steiner V, et al. (1997)
TRAMP, a novel apoptosis-mediating receptor with sequence homology to
tumor necrosis factor receptor 1 and Fas (Apo-1/CD95). Immunity 6: 79–88.
5. Screaton GR, Xu XN, Olsen AL, Cowper AE, Tan R, et al. (1997) LARD:
a new lymphoid-specific death domain containing receptor regulated by
alternative pre-mRNA splicing. Proc Natl Acad Sci U S A. 94: 4615–4619.
6. Papadakis KA, Prehn JL, Landers C, Han Q, Luo X, et al. (2004) TL1A
synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human
T cells and NK cells. J Immunol 172: 7002–7007.
7. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, et al. (2002) TL1A is a TNF-
like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.
Immunity 16: 479–492.
8. Kim S, Zhang L (2005) Identification of naturally secreted soluble form of
TL1A, a TNF-like cytokine. J Immunol Methods 298: 1–8.
9. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, et al. (2006) Interactions
of tumor necrosis factor (TNF) and TNF receptor family members in the mouse
and human. J Biol Chem 281: 13964–13971.
10. Jin T, Guo F, Kim S, Howard A, Zhang YZ (2007) X-ray crystal structure of
TNF ligand family member TL1A at 2.1A. Biochem Biophys Res Commun 364:
1–6.
11. Tan KB, Harrop J, Reddy M, Young P, Terrett J, et al. (1997) Characterization
of a novel TNF-like ligand and recently described TNF ligand and TNF receptor
superfamily genes and their constitutive and inducible expression in hemato-
poietic and non-hematopoietic cells. Gene 204: 35–46.
12. Bamias G, Martin C 3rd, Marini M, Hoang S, Mishina M, et al. (2003)
Expression, localization, and functional activity of TL1A, a novel Th1-polarizing
cytokine in inflammatory bowel disease. J Immunol 171: 4868–4874.
13. Bamias G, Mishina M, Nyce M, Ross WG, Kollias G, et al. (2006) Role of TL1A
and its receptor DR3 in two models of chronic murine ileitis. Proc Natl Acad
Sci U S A 103: 8441–8446.
14. Tian F, Grimaldo S, Fujita M, Cutts J, Vujanovic NL, et al. (2007) The
endothelial cell-produced antiangiogenic cytokine vascular endothelial growth
inhibitor induces dendritic cell maturation. J Immunol 179: 3742–3751.
15. Prehn JL, Thomas LS, Landers CJ, Yu QT, Michelsen KS, et al. (2007) The T
cell costimulator TL1A is induced by FcgammaR signaling in human monocytes
and dendritic cells. J Immunol 178: 4033–4038.
16. Meylan F, Davidson TS, Kahle E, Kinder M, Acharya K, et al. (2008) The
TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory
diseases. Immunity 29: 79–89.
17. Pappu BP, Borodovsky A, Zheng TS, Yang X, Wu P, et al. (2008) TL1A-DR3
interaction regulates Th17 cell function and Th17-mediated autoimmune
disease. J Exp Med 205: 1049–1062.
18. Schreiber TH, Wolf D, Tsai MS, Chirinos J, Deyev VV, et al. (2010)
Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung
inflammation. J Clin Invest 120: 3629–3640.
19. Taraban VY, Slebioda TJ, Willoughby JE, Buchan SL, James S, et al. (2011)
Sustained TL1A expression modulates effector and regulatory T-cell responses
and drives intestinal goblet cell hyperplasia. Mucosal Immunol 4: 186–196.
20. Meylan F, Song YJ, Fuss I, Villarreal S, Kahle E, et al. (2011) The TNF-family
cytokine TL1A drives IL-13-dependent small intestinal inflammation. Mucosal
Immunol 4: 172–185.
21. Heidemann SC, Chavez V, Landers CJ, Kucharzik T, Prehn JL, et al. (2010)
TL1A selectively enhances IL-12/IL-18-induced NK cell cytotoxicity against
NK-resistant tumor targets. J Clin Immunol 30: 531–538.
22. Fang L, Adkins B, Deyev V, Podack ER (2008) Essential role of TNF receptor
superfamily 25 (TNFRSF25) in the development of allergic lung inflammation.
J Exp Med 205: 1037–1048.
23. Buchan SL, Taraban VY, Slebioda TJ, James S, Cunningham AF, et al. (2012)
Death receptor 3 is essential for generating optimal protective CD4+ T-cell
immunity against Salmonella. Eur J Immunol 42: 580–588.
24. Twohig JP, Marsden M, Cuff SM, Ferdinand JR, Gallimore AM, et al. (2012)
The death receptor 3/TL1A pathway is essential for efficient development of
antiviral CD4+ and CD8+ T-cell immunity. FASEB J 26: 3575–3586.
25. Bayry J (2010) Immunology: TL1A in the inflammatory network in autoimmune
diseases. Nat Rev Rheumatol 6: 67–68.
26. Meylan F, Richard AC, Siegel RM (2011) TL1A and DR3, a TNF family
ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyper-
plasia, and autoimmune inflammation. Immunol Rev 244: 188–196.
27. Mainiero F, Gismondi A, Soriani A, Cippitelli M, Palmieri G, et al. (1998)
Integrin-mediated ras-extracellular regulated kinase (ERK) signaling regulates
interferon gamma production in human natural killer cells. J Exp Med 188(7):
1267–1275.
28. Gout S, Morin C, Houle F, Huot J (2006) Death receptor-3, a new E-Selectin
counter-receptor that confers migration and survival advantages to colon
carcinoma cells by triggering p38 and ERK MAPK activation. Cancer Res 66:
9117–9124.
29. Jones GW, Stumhofer JS, Foster T, Twohig JP, Hertzog P, et al. (2011) Naive
and activated T cells display differential responsiveness to TL1A that affects
Th17 generation, maintenance, and proliferation. FASEB J 25: 409–419.
30. Guicciardi ME and Gores GJ (2009) Life and death by death receptors. FASEB J
23: 1625–1637.
31. Kamada N, Hisamatsu T, Honda H, Kobayashi T, Chinen H, et al. (2010)
TL1A produced by lamina propria macrophages induces Th1 and Th17
immune responses in cooperation with IL-23 in patients with Crohn’s disease.
Inflamm Bowel Dis 16: 568–575.
32. Bull MJ, Williams AS, Mecklenburgh Z, Calder CJ, Twohig JP, et al. (2008) The
Death Receptor 3–TNF-like protein 1A pathway drives adverse bone pathology
in inflammatory arthritis. J Exp Med. 205(11): 2457–2464.
33. Cassatella MA, Pereira-da-Silva G, Tinazzi I, Facchetti F, Scapini P, et al. (2007)
Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated
monocytes in rheumatoid arthritis. J Immunol178: 7325–7333.
34. Zhang J, Wang X, Fahmi H, Wojcik S, Fikes J, et al. (2009) Role of TL1A in the
pathogenesis of rheumatoid arthritis. J Immunol 183: 5350–5357.
35. Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, et al. (2007)
Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation.
Immunity 26: 371–381.
TL1A Modulates B-Cell Proliferation
PLOS ONE | www.plosone.org 11 April 2013 | Volume 8 | Issue 4 | e60136
